[ad_1]
Pancreatic cancer is often fatal and has not changed much in the last four decades, but there is now a potential breakthrough. A simple blood test to detect the disease early enough to make a difference. Joe Marino is dedicated to the fight against pancreatic cancer. Through golf tournaments, challenging challenges and even ice cream sales, he raises funds to help those affected because he has been in their shoes. "Five years ago, when I was announced that I had a pancreatic tumor, I have like" I will not be there in a year, "said Marino. He had initially gone to see his doctor for stomach pain and thought the cause was gallstones. She sent him an ultrasound that revealed a four-centimeter spot on his pancreas. "It was a fortuitous discovery, which is the only reason I am still here today because there is currently no early detection test," said Marino. "It's a clinical need that Mats Grahn, president and CEO of Immunovia, molecular diagnostics company, has come up with a potential solution called IMMray PanCan-d. It's a Blood test for early detection of pancreatic cancer. "It's like a fingerprint that changes in appearance if you're healthy and if you're sick," Grahn said. The process begins with the following: Sending a standard blood test to the company's laboratory where researchers focus on the protein patterns in the blood. "We add a marker of resistance to blood, to all blood proteins we apply it to our microchip where antibodies are found. Each antibody measures the concentration of a particular protein, "Grahn said. This chip is placed in a machine for analysis where diseased cells differentiate from healthy cells. Clinical trials are underway with results The results published in the Journal of Clinical Oncology show that the system was 96% accurate for the detection of stage 1 and 2 pancreatic cancer cases. "Early discovery can make all the difference, as Marino knows. After a complex operation that took away some of his pancreas, he recently celebrated five years without cancer, paying for it by giving back to a growing group of survivors on fundraising marches, including a recent event at Boston by Pancreatic Cancer Action. "I saw survivors aged 18 to 6 months all together. We save the lives of others, we let people live, giving them hope, "said Marino.IMMray PanCan-d would be for patients with an increased risk of developing the disease.For example, people with a close relative died next year, the company will launch a test developed in the laboratory.The approval of the Food and Drug Administration could come in the next few years.In the meantime, the company is leading a clinical trial, PanFAM-1, an ongoing validation study for early diagnosis of pancreatic cancer in high-risk individuals with familial pancreatic cancer.There are two sites in Massachusetts. 39, one at Massachusetts General Hospital in Boston, the other at UMass Memorial Medical Center in Worcester.
Pancreatic cancer is often fatal and has not changed much in the last four decades, but there is now a potential breakthrough. A simple blood test to detect the disease early enough to make a difference.
Joe Marino is dedicated to the fight against pancreatic cancer. Through golf tournaments, challenging challenges, even ice cream sales, he raises funds to help those affected because he has been in their shoes.
"Five years ago, when I was announced that I had a pancreatic tumor, I googled it and I told myself:" I will not be there in a year ", said Marino.
Originally, he went to see his doctor for stomach pain and thought that gallstones were the cause. She sent him an ultrasound that revealed a four-centimeter spot on his pancreas. He was 36 years old and faced a diagnosis he did not expect.
"It was a fortuitous discovery, which is the only reason I am still here today because there is currently no early detection test," Marino said.
"There is a clinical need that is absolutely not satisfied, there is nothing in it," said Mats Grahn, president and chief executive officer of the company. Immunovia, a molecular diagnostic company.
The company has developed a potential solution called IMMray PanCan-d. This is a blood test for early detection of pancreatic cancer.
"It's like a fingerprint that looks different if you're healthy and if you're sick," Grahn said.
The process begins with a standard blood sample sent to the company's laboratory, where researchers focus on the protein patterns in the blood.
"We add a fluorescence marker to blood, to all blood proteins, and apply it to our microchip where antibodies are found.Every antibody measures the concentration of a particular protein," Grahn said.
This chip is placed in a machine for analysis where the diseased cells are differentiated from healthy cells. Clinical trials are underway with promising preliminary results.
The results published in the Journal of Clinical Oncology show that the system was 96% accurate in detecting cases of pancreatic cancer in stages 1 and 2.
Early discovery can make all the difference, as Marino knows. After a complex operation that took away some of his pancreas, he recently celebrated his 5 years without cancer.
He repays it by reconnecting and connecting with a growing group of survivors on fundraising marches, including a recent event in Boston organized by the Pancreatic Cancer Action Network.
"I saw survivors aged 18 to 6 months all together, we save the lives of others, we let people live, giving them hope," Marino said.
IMMray PanCan-d is intended for patients at increased risk of developing the disease. For example, people with a close relative who died of pancreatic cancer. Next year, the company will launch a test developed in the laboratory. The approval of the Food and Drug Administration could come in the next few years.
In the meantime, the company is conducting a clinical trial, PanFAM-1, an ongoing validation study for the early diagnosis of pancreatic cancer in high-risk individuals with familial pancreatic cancer. There are two sites in Massachusetts. One at Massachusetts General Hospital in Boston, the other at UMass Memorial Medical Center in Worcester.
Alert me
[ad_2]
Source link